Assuming that the percentage of patients showing an increase in serum vitamin B12 concentration to above 179 pg/ml in both groups is 70%, means the study requires at least 304 patients (152 in each arm) for a threshold of non-inferiority of 10% and a statistical power of 60% with significance set at p 179 pg/ml: patient preference questionnaire Randomisation of patients to treatment group Visit 1 (start of treatment) Anamnesis: record whether the patient lives alone or with others, lifestyle habits, use of alcohol, whether a vegan diet is followed, whether the patient has undergone gastrectomy Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in state of mind, concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Questionnaires: Lobo cognitive mini-exam, EuroQoL-5D Record concomitant treatment Request analyses to be performed one week before next visit: haemogram and serum vitamin B12 Therapeutic plan: patient in oral arm provision of medication

These molecular changes suggest that the dysregulation of inflammation and oxidative stress-related genes may play a central role in the pulmonary toxicity induced by mercury
The marginal benefit of adding AOD 9604 to a protocol that is already delivering 20%+ body weight reduction is questionable
CI: 469651), vitamin C (51 mg
MK-677 (half-life 24 hours) requires a longer taper 3-4 weeks minimum because its prolonged receptor occupancy causes deeper suppression that takes 28-35 days to fully resolve
They lower blood glucose levels, slow gastric emptying, lower serum cholesterol and triglyceride levels, reduce liver fat content, decrease the highly inflammatory visceral fat, enhance microvascular (!) blood flows in the muscle tissue, reduce muscle-produced inflammation, microglial activation (neuroinflammation), and enhance neuroplasticity